How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 diabetes and established cardiovascular (CV) disease, empagliflozin given in addition to standard of care reduced the risk of CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS: Effects of potential mediators, identified post hoc, on the HR for CV death with empagliflozin versus placebo were analyzed by Cox regression models, with treatment group adjusted for the baseline value of the variable and its change from baseline or updated mean (i.e., considering all prior values), each as a time-dependent covariate. HRs were compared with a model without adjustment for covariates. Multivariable analyses also were performed. RESULTS: Changes in hematocrit and hemoglobin mediated 51.8% and 48.9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means. Smaller mediation effects (maximum 29.3%) were observed for uric acid, fasting plasma glucose, and HbA1c. In multivariable models, which incorporated effects of empagliflozin on hematocrit, fasting glucose, uric acid, and urine albumin:creatinine ratio, the combined changes from baseline provided 85.2% mediation, whereas updated mean analyses provided 94.6% mediation of the effect of empagliflozin on CV death. CONCLUSIONS: In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both have been identified as important determinants of the heart failure benefits of these drugs in trials of patients with type 2 diabetes.”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [32]
In the citing paper
“Those that appear particularly plausible include effects on volume status, natriuresis, expansion of red blood cell mass, and myocardial energetics (34,36,59,62,64).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
In the citing paper
“Thus, the mechanisms by which SGLT2 inhibitors reduce the risk for HF are not attributable to improved glycemic control (59).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
Citations
Cites
Baron, R. M., & Kenny, D. A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.51.6.1173 · Cited by 91,532 · cited 2×
“A traditional mediation analysis as originally proposed by Baron and Kenny (12) was used, taking the time-dynamic evolvement of both the potential mediators and the outcome CV death into account.”
Method(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationUric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundSelf-citationLow Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155 · cited 1×
“Therefore, many participants in this trial likely had unrecognized left ventricular dysfunction, particularly diastolic dysfunction, which may eventually lead to clinical heart failure with preserved ejection fraction (25).”
Background
Research works printed but not linked: 2
- Fitchett, Further exploration of the cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease in EMPA-REG OUTCOME, J Am Coll Cardiol
- Boehringer Ingelheim. Empagliflozin (Jardiance®) to be studied in chronic kidney disease. 2017. Available from https://www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease. Accessed 6 September 2017
Cited by
Items 501–600 of 762
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P. H., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.031847 · Cited by 6
SGLT-2 Inhibitors in Heart Failure
Kosiborod, M., & Vaduganathan, M. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.005 · Cited by 6
Trialing precision medicine for type 2 diabetes
Pilla, S. J., Mathioudakis, N. N., & Maruthur, N. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02168-5 · Cited by 6
Sun, W., Kong, A. P. S., & Yan, B. P. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277321 · Cited by 5
Guiraud, V., Sauce, D., Bittar, R., Fernández, J., Thévenet, H., Teyssou, E., Alkouri, R., Bonnefont‐Rousselot, D., Marcelin, A., Cálvez, V., et al. (2025) · Infectious Diseases Now · doi:10.1016/j.idnow.2025.105040 · Cited by 6
Goodluck, H., Zemljic‐Harpf, A. E., Galdino, O. A., Kanoo, S., Lopez, N., Kim, Y., & Vallon, V. (2025) · Physiological Reports · doi:10.14814/phy2.70217 · Cited by 5
Bhandari, K., Qadri, M., Dhakal, R., Ghimire, S., Jora, G., Basyal, S., & Shah, S. K. (2025) · Cardiovascular Therapeutics · doi:10.1155/cdr/6649731 · Cited by 5
“The resultant volume contraction and hemoconcen-tration were attributed as the cause of reduction in cardiovascular mortality in a mediation analysis of the EMPA-REG outcome trial [68].”
SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope?
Brusnic, O., Onișor, D. M., Boicean, A., Porr, C., Sofonea, F., Anderco, P., & Ichim, C. (2025) · Life · doi:10.3390/life15121788 · Cited by 5
“Across cardiovascular outcome data, on-treatment rises in hematocrit and hemoglobin were the strongest mediators of the reduction in cardiovascular death with empagliflozin, supporting these as practical response markers [167,168].”
Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
Mkrtumyan, A. M., Маркова, Т. Н., & Mishchenko, N. K. (2021) · Diabetes Mellitus · doi:10.14341/dm12541 · Cited by 8
Tabella, E., Correale, M., Alcidi, G., Pugliese, R., Ioannoni, S., Romano, M., Palmieri, G., Biase, M. D., Brunetti, N. D., & Iacoviello, M. (2023) · Clinics and Practice · doi:10.3390/clinpract13050090 · Cited by 5
“Moreover, the increased cardiac delivery of oxygen due to the elevated hematocrit and the reduction of afterload could potentially enhance ventricular function [18].”
BackgroundEljadid, G. Y., Rakab, M. S., Mansour, A., Almosilhy, N. A., Abbas, A. W., Abdrabou, N., Alarab, A. S., Mohamed, Y. A., Khaled, A., Goufa, E., et al. (2024) · Cureus · doi:10.7759/cureus.69229 · Cited by 7
“Patients with CHD have been shown to benefit from empagliflozin in multiple clinical trials [9,10].”
BackgroundEbrahimi, P., Soleimani, H., Mahalleh, M., Farisi, P., Taheri, M., Ramezani, P., Soltani, P., Nazari, R., Senobari, N., Mousavinezhad, S. M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01545-w · Cited by 6
Clinical and biochemical profile of individuals with renal glucosuria: A matched cohort study
Nakhleh, A., Adler, L., Ayada, G., David, S. S. B., Rahamim‐Cohen, D., Liran, O., Zolotov, S., & Shehadeh, N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16339 · Cited by 5
“18 In our study, the prevalence of genital infections (13.2% and 12.3%, respectively; p = 0.72) and urinary tract infections (8.2% and 6.5%, respectively; p = 0.40) was comparable between individuals with renal glucosuria and controls.”
InfluentialDisease-modifier Drugs in Patients with Advanced Heart Failure
Iacoviello, M., Vitale, E., Corbo, M. D., Correale, M., & Brunetti, N. D. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.05.002 · Cited by 5
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Mordi, I. R., & Lang, C. C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.004 · Cited by 5
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors
Kugathasan, L., Dubrofsky, L., Advani, A., & Cherney, D. Z. I. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2159810 · Cited by 5
“Likewise, mediation analyses from the EMPA-REG OUTCOME and CANVAS trials reported negligible effects of BP reduction as a mediator of clinical outcome [109,110].”
MethodSGLT2 Inhibitors and Kidney Diseases: A Clinical Perspective
Theofilis, P., & Kalaitzidis, R. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221227091943 · Cited by 6
The emerging concept of glycocalyx damage as the trigger of heart failure onset and progression
Targoński, R., Kowacz, M., Oraczewski, R., Thoene, M. A., & Targoński, R. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111234 · Cited by 5
SGLT2 inhibitors: expanding their Empire beyond diabetes
Muskiet, M. H. A., Heerspink, H. J. L., & van Raalte, D. H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30428-9 · Cited by 5
Vlasschaert, C., Sidhu, B., & Silver, S. A. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000703 · Cited by 5
Monda, V. M., Porcellati, F., Strollo, F., Fucili, A., Monesi, M., Satta, E., & Gentile, S. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01791-x · Cited by 6
Gitto, M., Vrachatis, D. A., Condorelli, G., Papathanasiou, K. A., Reimers, B., Deftereos, S. G., & Stefanini, G. G. (2021) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525719666210809121016 · Cited by 5
Nayak, S., Rathore, V., Bharati, J., & Sahu, K. K. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.2028620 · Cited by 5
“In a post hoc analysis of the EMPA-REG trial, 50% of CV risk reduction is believed to be mediated through a change in hematocrit and hemoglobin [83].”
MethodEditorial: Heart Failure in Type 2 Diabetes – The “Forgotten” Complication
Guja, C., & Miulescu, R. D. (2018) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2018-0014 · Cited by 5
“In addition, SGLT2i treatment is associated with an increase in hematocrit and red blood cell mass (Hb), that may lead to an increase in oxygen delivery to the heart [35].”
BackgroundEffect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes
Reutens, A. T., Lekamlage, D. H., Salim, A., Shaw, J. E., Esler, M., Cooper, M. E., & Kaye, D. M. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102304 · Cited by 6
Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists
Siddiqi, A. K., Khan, M. S., Kulkarni, A., Hall, M. E., Böhm, M., Díez, J., & Butler, J. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01342-7 · Cited by 5
Moghadam, S. A., Shahmohammadi, A., Salehi, K., Javid, R. N., Soltani, P., Zafarmandi, S., Shafieyoun, M. H., Mahalleh, M., Ahmed, R., Bekfani, T., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag027 · Cited by 4
“15 This highlights the importance of Hb and Hct correction in reducing cardiovascular risks among patients treated with SGLT2 inhibitors.”
Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms
BAJAJ, H. S., & Zinman, B. (2018) · Physiology · doi:10.1152/physiol.00004.2018 · Cited by 7
“Contrary to explanations for GLP-1 RA, both the leading mechanistic hypotheses for cardiovascular benefits of SGLT2 inhibitors—the hemodynamic (64, 93) and the “thrifty substrate” (39) hypotheTa b le 2 .”
BackgroundMethodResultSelf-citationPiepoli, M. F., Rosano, G. M. C., Abreu, A., Adamo, M., Attanasio, A., Chioncel, O., Solal, A. C., Filippatos, G., Gerdts, E., Gevaert, A. B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehag362 · Cited by 7
Son, M., Lee, Y. S., Hong, A. R., Yoon, J. H., Kim, H. K., Kang, H., & Yang, S. H. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07067-w · Cited by 4
“Nonetheless, according to a mediation analysis from the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients—Removing Excess Glucose (EMPA-REG OUTCOME) study, increases in hemoglobin and hematocrit are among the most important factors associated with improved cardiovascular outcomes [1…”
MethodSukhareva, O. Y., Zuraeva, Z. T., & Shamhalova, M. (2022) · Diabetes Mellitus · doi:10.14341/dm12864 · Cited by 4
Zhang, X., Zhang, Y., & Hu, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1039348 · Cited by 6
Васильевна, Ц. О., Тимощенко, О. В., Tuzovskaia, O. V., Latyntseva, L. D., & Nikolaev, К. Y. (2022) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20220601 · Cited by 4
Sharma, A., Butler, J., Zieroth, S. R., Giannetti, N., & Verma, S. (2019) · Diabetic Medicine · doi:10.1111/dme.14140 · Cited by 4
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 5
Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease
Oguz, F., Demoulin, N., Thissen, J. P., Jadoul, M. Y., & Morelle, J. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.1966583 · Cited by 5
“the heart, and mediation analyses from EMPA-REG OUTCOME indicated that the rise in hematocrit is a key determinant of the cardiovascular death benefit [43].”
MethodSerum uric acid: a mediator of cardio-reno-metabolic diseases
Katsiki, N., & Athyros, V. G. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.2021071 · Cited by 4
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Yagyu, H., & Shimano, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13859 · Cited by 4
Schneider, C. A., & Pfister, R. (2022) · Herz · doi:10.1007/s00059-022-05134-6 · Cited by 4
Shikuma, J., Sakakura, K., Sugiyama-Takahashi, M., Nakamura, Y., Nagai, Y., Suwanai, H., Ito, R., Miwa, T., & Suzuki, R. (2022) · Medicine · doi:10.1097/md.0000000000031122 · Cited by 5
“[3] Although administration of SGLT2 inhibitors increases the hematocrit level by approximately 2% to 4%, a post hoc analysis of EMPA-REG OUTCOME trials reports that this increase was most commonly associated with reduced cardiovascular death.[4] Increased hematocrit (ΔHct) level is not caused by hemoconcentration due…”
BackgroundRoy, S. (2019) · Cureus · doi:10.7759/cureus.4352 · Cited by 4
“Increased Hematocrit level in EMPAREG outcome (Trial number NCT01131676) has been attributed to be a major cardiovascular benefit contributing factor [8].”
Backgroundfor SingHypertension Study Group, Allen, J. C., Halaand, B., Shirore, R. M., & Jafar, T. H. (2021) · Trials · doi:10.1186/s13063-020-05016-4 · Cited by 7
Gill, M. P., Leung, M., Luo, C., Cheung, C., Beauchesne, A., Chang, D., Lan, J. H., & Johnston, O. (2023) · Clinical Transplantation · doi:10.1111/ctr.15013 · Cited by 4
Chen, L., Zuo, Y., He, M., Duo, L., & Tang, W. (2024) · Journal of International Medical Research · doi:10.1177/03000605241272639 · Cited by 3
Empagliflozin and fluid balance: results from the SiRENA project
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf262 · Cited by 3
Sridhar, V. S., Kugathasan, L., Lytvyn, Y., Deng, Y., Liu, H., Lovblom, L. E., TSE, J. M., Nardone, M., Floras, J. S., Osuntokun, T., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25955 · Cited by 3
Koshino, A., Neuen, B. L., Oshima, M., Toyama, T., Hara, A., Arnott, C. G., Neal, B. C., Jardine, M., Badve, S. V., Mahaffey, K. W., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.11.024 · Cited by 3
“21-23 There is evidence that SGLT2 inhibitors transiently increased EPO levels and this could explain at least part of the bene fi cial effect observed for anemia.”
BackgroundMaruhashi, T., Tanaka, A., Takahashi, K., Higashi, Y., Node, K., & the PROCEED trial investigators (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15481 · Cited by 3
“3 In addition, multiple post-hoc mediation analyses of the CANVAS Program showed that increase in erythrocyte concentration was one of the strongest mediators of risk reductions in heart failure and kidney outcomes associated with cana-gliflozin treatment.”
BackgroundAl Hejji, R. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.18.003173 · Cited by 3
A Longitudinal Study on Hematocrit Changes after Glifozins Exposure in Patients with Type 2 Diabetes
Instituto de Gestión Sanitaria (INGESA), Á. S. D. M., López, D. L. N., Robles Mateos, C., Instituto de Gestión Sanitaria (INGESA), Á. S. D. M., Soria Cano, J. J., Instituto de Gestión Sanitaria (INGESA), Á. S. D. M., Barón Fernandez, O., Instituto de Gestión Sanitaria (INGESA), Á. S. D. M., Dominguez Lomeña, M. J., Instituto de Gestión Sanitaria (INGESA), Á. S. D. M., et al. (2021) · Journal of Cardiovascular Disorders · doi:10.26420/jcardiovascdisord.2021.1044 · Cited by 3
Diabetes: how to manage cardiovascular risk in secondary prevention patients
Anderson, S. L., & Marrs, J. C. (2022) · Drugs in Context · doi:10.7573/dic.2021-10-1 · Cited by 3
Ketone Bodies in Acute Heart Failure: Fuel for Thought
Manla, Y., Kuan, W., Clark, A. L., Cleland, J. G. F., & Pellicori, P. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.11.002 · Cited by 3
Miñana, G., de la Espriella, R., Palau, P., Amiguet, M., Seller, J., Pinilla, J. M. G., Núñez, E., Górriz, J. L., Valle, A., Sanchís, J. M., et al. (2023) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.03.006 · Cited by 3
Li, Y., Zhang, Z., Zhang, Z., Zheng, N., & Ding, X. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31264 · Cited by 4
“Of note, in the EMPA ‐ REG OUTCOME study by Inzucchi et al. (2018), increased hematocrit accounted for more than 50% of the benefit in major adverse cardiovascular events, suggesting that the cardioprotective effects of EMPA may be partly due to its erythropoietic effects.”
BackgroundНиколаевна, К. О., Korotkov, D. A., Sazhina, A. S., & Bogomolov, A. N. (2024) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2024-3014 · Cited by 3
Steinmetz, T., Goldman, S. N., Kagan, K. B. T., Bielopolski, D., Buchrits, S., Schechter, A., Kushnir, S., Turjeman, ., Agur, T., Grossman, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf184 · Cited by 3
Jiménez, D. L., Huelgas, R. G., Romero, A. J. F., Chozas, J. M. L., de Isla, L. P., & Miramontes‐González, J. P. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2018.09.021 · Cited by 3
Jiménez, D. L., Huelgas, R. G., Romero, A. J. F., Chozas, J. M. L., de Isla, L. P., & Miramontes‐González, J. P. (2019) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.01.001 · Cited by 3
Strategy and tactics of treatment of type 2 diabetes mellitus
Kvapil, M. (2019) · Vnitřní lékařství · doi:10.36290/vnl.2019.046 · Cited by 3
Müller‐Wieland, D., Brandts, J., Verket, M., Marx, N., & Schütt, K. S. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_537 · Cited by 4
Jędrzejewska, A., Braczko, A., Kawecka, A., Hellmann, M., Siondalski, P., Slominska, E. M., Kutryb-Zając, B. A., Yacoub, M. H., & Smolenski, R. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179886 · Cited by 3
Effect of Empagliflozin on Serum Levels of Thyroid Hormones Among Prediabetic and Diabetic Patients
Sanjari, M., Sadeghi, N., Amirkhosravi, L., Hadavizadeh, M., Naghibzadeh‐Tahami, A., & Safi, Z. (2025) · International Journal of Endocrinology · doi:10.1155/ije/9920286 · Cited by 2
“Empaglifozin signifcantly afects arterial stifness, albuminuria and plasma urate and increases low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels [21, 22].”
Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial
Andersen, C. F., Larsen, J. H., Omar, M., Nouhravesh, N., Kistorp, C., Tuxen, C., Knop, F. K., Madsen, P. L., Forman, J. L., Davidovski, F. S., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag010 · Cited by 2
Glucosuria as a Biomarker of Adherence to Sodium-Glucose Co-Transporter Protein Type 2 Inhibitors
Escribano‐Serrano, J., Jiménez‐Varo, E., Escribano-Cobalea, M., Casto-Jarillo, C., López-Ceres, A., Campos-Dávila, E., Pozo, A. H., Franch‐Nadal, J., & Doña, A. M. (2026) · Patient Preference and Adherence · doi:10.2147/ppa.s576212 · Cited by 2
“Furthermore, hemoglobin and hematocrit were lower in patients, both men and women, with absent glucosuria in urine samples (p<0.05 for both variables) (Figure 5).”
InfluentialJanssen, J. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052150 · Cited by 2
SGLT2 Inhibitors in Alzheimer’s Disease: Biochemical Insights and Therapeutic Potential
Mazzeo, P., Vietri, M., Tecce, N., Delizia, A., Remondelli, V., Ciaglia, T., Dio, A. D., Corletti, L., Pizzuti, C. G., Pepe, G., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115051 · Cited by 2
“At the metabolic level, inhibition of the SGLT2 isoform induces a shift in glucose metabolism characterized by increased fat oxidation and ketogenesis, together with reduced carbohydrate utilization (Table 1) [17].”
Marques, P. S., Vasques‐Nóvoa, F., Pintalhão, M., Bergantim, R., Mendonça, L., Neves, J. S., Friões, F., Sharma, A., Filipatos, G., Butler, J., et al. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106989 · Cited by 2
Physiology of Kidney Glucose Transport and Mechanisms of Kidney Protection by SGLT2 Inhibitors
Vallon, V. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_828 · Cited by 4
Kuwabara, M., Cicero, A. F. G., Akashi, N., Oginö, K., Ae, R., Kohro, T., Kosami, K., Kojima, S., Kanbay, M., Andrés-Hernando, A., et al. (2026) · Journal of Cardiology · doi:10.1016/j.jjcc.2026.07.009 · Cited by 2
Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME
Fisher, M. (2020) · British Journal of Diabetes · doi:10.15277/bjd.2020.254 · Cited by 2
Beyond the myocardium: Sodium‐glucose co‐transporter‐2 inhibitors in heart failure
CHILTON, R. J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14320 · Cited by 2
“9% of this effect, respectively.(9) This is supported by data from a trial investigat-”
ResultMcGuire, D. K., Inzucchi, S. E., Johansen, O. E., Rosenstock, J., George, J. T., & Marx, N. (2021) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-020-00295-3 · Cited by 2
“In addition, an exploratory mediation analysis of EMPA-REG OUTCOME data found that changes in hemoglobin/hematocrit and in albumin (indirect markers of plasma volume) were the most important mediators of the reduction in risk; any association between HbA1c and outcomes was quite modest [11].”
Self-citationIs there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors
KHAKDE, S., Jawaid, H., Yasmin, F., Ali, M. B., & REHMAN, A. (2022) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03221-6 · Cited by 2
Golubovskaia, D. P., Каретникова, В. Н., Олейник, И. Р., & Барбараш, О. Л. (2022) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2022-10-08 · Cited by 3
SGLT2 Inhibitors: Emerging Drugs in Heart Failure
Cho, D. (2023) · Korean Journal of Medicine · doi:10.3904/kjm.2023.98.2.59 · Cited by 2
Stability Indicating Assay of Empaglifozin and Metformin
Sahu, L. K., Si, S., & Patro, S. K. (2024) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2024.00177 · Cited by 2
Fawzi, H. A., Sabbar, R., Kadhim, S. A. A., Flayih, A., Mohammad, B. I., & Swadi, A. A. (2024) · Journal of Medicine and Life · doi:10.25122/jml-2023-0340 · Cited by 2
“This makes EMPA a valuable addition to the standard treatments of patients with T2DM and pre-existing cardiovascular disease by reducing cardiovascular events, cardiovascular mortality, and the incidence or progression of nephropathy; it also significantly reduces myocardial fibrosis [14].”
BackgroundResultBibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
Pan, R., He, Y., Melisandre, W., Zhang, Y., Su, W., Feng, J., Jia, C., Li, S., & Liu, B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1437760 · Cited by 2
Ferrannini, E., Baldi, S., Scozzaro, T., Ferrannini, G., & Hansen, M. K. (2024) · JCI Insight · doi:10.1172/jci.insight.180637 · Cited by 3
“SGLT2-induced changes in hemodynamics (e.g., higher hematocrit, lower blood pressure, decreased interstitial fluid accumulation and oxygen delivery, e.g., higher blood hemoglobin) plausibly concur with the metabolic shifts to influence cardio-renal outcomes (Figure 6) (27, 28).”
Self-citationJACOBS, G., EMBLIN, K., Kadam, U. T., DANIELS, R., ALALLAN, M., & Mokbel, K. (2024) · In Vivo · doi:10.21873/invivo.13859 · Cited by 2
“Savage et al. (61) provided an excellent summary of these mechanisms: SGLT2 inhibitors can enhance natriuresis secondary to glycosuria (65), lower blood pressure (66), boost ketone and fatty acid use thereby reducing HF remodelling (67), inhibit proinflammatory pathways (68), inhibit myocardial…”
Ito, H., Someya, R., Koyanagi, T., Chiaki, I., Miura, S., Matsumoto, S., Inoue, H., Antoku, S., Yamasaki, T., Mori, T., et al. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70032 · Cited by 2
“Previous mediation analyses in patients with type 2 diabetes have shown that an increase in serum albumin concentration after SGLT2 therapy contributes to the prevention of cardiovascular and renal events 21 – 23 .”
A nátrium-glükóz-kotranszporter-2-gátlók a diabetes mellitus kezelésén túl
Szekeres, Z. J., Stolcz, T., & Szabados, E. (2020) · Cardiologia Hungarica · doi:10.26430/chungarica.2020.50.5.372 · Cited by 2
“Az EMPA-REG OUTCOME-vizsgálat eredményei alapján a hematokrit és a hemoglobin növekedése voltak a legfontosabb mediátorok a kardiovaszkuláris rizikó csökkentésében (9).”
FULMINANT MYOCARDITIS-A UNIQUE COMPLICATION OF COVID-19
Ahmed, A., Young, S. K., & Lantz, R. H. (2021) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(21)03378-7 · Cited by 2
Lo scompenso cardiaco a 360 gradi
Gnerre, G. E. P., & Pasquale, G. D. (2021) · Italian Journal of Medicine · doi:10.4081/itjm.q.2021.2 · Cited by 2
Povetkin, S. V. (2021) · Человек и его здоровье · doi:10.21626/vestnik/2021-1/03 · Cited by 2
Nashawi, M., Ahmed, M. S., Amin, T., Abualfoul, M., & CHILTON, R. J. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i12.676 · Cited by 2
Reduction in heart failure outcomes with SGLT2 inhibitors irrespective of glycaemic status
Gerstein, H. C., & Sattar, N. A. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00313-8 · Cited by 2
Метаболічні ефекти інгібіторів натрійзалежного котранспортера глюкози 2 типу
Кедик, А. В., & Kutsin, O. O. (2022) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2022-4-42 · Cited by 2
“Субаналіз EMPA-REG OUTCOME показав незначний внесок зниження рівня HbA1c у виявлені у РКД кардіопротекторні ефекти емпагліфлозину [59].”
Lifestyle Interventions in Diabetes and Coronary Disease
Farkouh, M. E., & Godoy, L. C. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.12.091 · Cited by 2
Seferovic, P. M., & Polovina, M. M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1981 · Cited by 2
Can CMR Elucidate the Cardiovascular Benefit of SGLT2 Inhibitors?
Nicholls, S. J., & Nerlekar, N. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.11.003 · Cited by 3
Heart failure therapy in patients with diabetes
Tuccinardi, F. (2020) · The Journal of AMD · doi:10.36171/jamd20.23.2.5 · Cited by 1
Hussein, M. T. E., & Reeves, C. (2023) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2023.104716 · Cited by 1
Qarni, A. A. A., AlSubaiee, M., Husain, M., Alkhazmari, G., AlQahtani, A., Aldossary, I., Gado, W., Albahrani, Z., AlMukhaylid, S., Alarfaj, A., et al. (2023) · Series of Endocrinology Diabetes and Metabolism · doi:10.54178/jsedmv5i2004 · Cited by 2
Khoshnazar, S. M., Dehghani, A., Bagheri, F., Pezeshki, S., & Yousefzadeh, G. (2024) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2023.10.004 · Cited by 1
Ibraheem, A., & Tameemi, W. F. A. (2024) · Cureus · doi:10.7759/cureus.69837 · Cited by 1
“Beyond glycemic control, SGLT2 inhibitors have shown impressive cardio-renal benefits and a modest reduction in body weight and blood pressure in recent years [14-17].”
BackgroundResultSGLT-2 Inhibitors: The Magic Bullet for Cardio-Renal Protection in Type 2 DM
Patel, R., & Oroszi, T. L. (2024) · Pharmacology & Pharmacy · doi:10.4236/pp.2024.1512027 · Cited by 1
Heart Failure Treatment with SGLT2 Inhibitors: A Systematic Review with Meta-Analysis
Peres-Filho, F. P., da Silva, S. U., Peres, F. P., & Kerche, L. E. (2024) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20240060i · Cited by 5
Chung, C., Lu, H., Chung, M., Wu, L., Huo, C., Kuo, L., Liu, C., & Chuu, C. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040260 · Cited by 2
“39 The decline in serum uric acid may as well decrease the incidence of aortic dissection in patients with T2D.”
Kajiwara‐Morita, A., Oniki, K., Yoshida, A., Kurinami, N., Suzuki, T., MIYAMOTO, F., Hieshima, K., Sugiyama, S., Kajiwara, K., Jinnouchi, K., et al. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/5399360 · Cited by 1
Metadata
- Authors
- Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., Hantel, S., Bluhmki, E., & Lachin, J. M.
- Affiliations
- Yale University (US)
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Universitätsklinikum Würzburg (DE)
- Istituto di Fisiologia Clinica (IT)
- University of Freiburg (DE)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (Germany) (DE)
- George Washington University (US)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-04
- Volume
- 41
- Issue
- 2
- Pages
- 356-363
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2772204795
- Cited by
- 740
- References
- 33
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 71 · 2023: 83 · 2022: 103 · 2021: 109 · 2020: 139 · 2019: 96 · 2018: 56
- FWCI
- 62.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Eisai
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, cardiovascular mortality, mediation analysis, type 2 diabetes, EMPA-REG OUTCOME trial, hematocrit, hemoglobin, plasma volume, uric acid, fasting blood glucose, HbA1c, urine albumin-creatinine ratio, SGLT2 inhibitors
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Dose-Response Relationship, Drug, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Placebos, Risk Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.